Clinical trials
Hypersensitivity trials in France with no applicable phase
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
37 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 1 |
| 2008 | 1 |
| 2010 | 2 |
| 2011 | 2 |
| 2012 | 3 |
| 2013 | 3 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 6 |
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 5 |
| 2023 | 1 |
| 2024 | 1 |
| 2026 | 4 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 19 |
| Unknown status | 8 |
| Recruiting | 6 |
| Terminated | 3 |
| Not yet recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Assistance Publique - Hôpitaux de Paris | 8 |
| Alyatec | 5 |
| Hospices Civils de Lyon | 4 |
| University Hospital, Montpellier | 4 |
| University Hospital, Clermont-Ferrand | 3 |
| Centre Hospitalier Universitaire de Nice | 2 |
| University Hospital, Limoges | 2 |
| Bledina | 1 |
| Centre Hospitalier Régional d'Orléans | 1 |
| Centre Hospitalier Universitaire Dijon | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hypersensitivity | 37 |
| Asthma | 4 |
| Food Hypersensitivity | 2 |
| Hypersensitivity, Immediate | 2 |
| Milk Hypersensitivity | 2 |
| Pain | 2 |
| Anaphylaxis | 1 |
| Anemia, Sickle Cell | 1 |
| Anxiety Disorders | 1 |
| COVID-19 | 1 |
Trials
Showing 1 to 25 of 37. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.